17.09.2014 • NewsAllerganBill AckmanBotox

Allergan Special Shareholder Meeting Set for December

US drugmaker Allergan, which makes the Botox anti-wrinkle treatment, said it has reached agreement with suitors Pershing Square Capital Management and Canada's Valeant Pharmaceuticals to hold a special shareholder meeting on the originally scheduled date of Dec. 18.

The two latter companies, closely tied to investment activist shareholder Bill Ackman, also have agreed to dismiss their pending litigation before the Delaware Court of Chancery, Allergan added.

Together Pershing Square, Allergan's largest shareholder with a 9.72% stake and Valeant made a $52 billion hostile offer for Allergan in April. In August, they sued the target company, alleging it was trying to avoid a special meeting to give it time to find an alternative deal. Allergan subsequently called the meeting for the December date.

Since the initial takeover approach, Allergan has been fighting for investor support for its own standalone plan that includes cost cuts and making an acquisition of its own.

To force the company to the table, Ackman has been pushing for a special meeting where he hopes to replace most board members with his own nominees, who he expects will be more receptive to Valeant's bid.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.